CX Institutional
SMMT icon

CX Institutional’s Summit Therapeutics SMMT Stock Holding History

CX Institutional’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$34K Buy
2,038
+1,447
+245% +$21.6K ﹤0.01% 1100
2026
Q2 		$9K Sell
591
-257
-30% -$4.56K ﹤0.01% 1314
2026
Q1 		$16K Buy
+848
New +$13.7K ﹤0.01% 1186

Other funds holding SMMT

Griffin Asset Management
Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Wealth Management Partners
Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

CX Institutional's SMMT Position: Q3 2026 in Review

CX Institutional increased its Summit Therapeutics (SMMT) stake by 245% in Q3 2026, buying an estimated $21.6K and bringing the position to 2,038 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

CX Institutional first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 37 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • CX Institutional held 2,038 shares of Summit Therapeutics worth $34K as of Q3 2026.
  • CX Institutional bought 1,447 Summit Therapeutics shares in Q3 2026, an estimated $21.6K.
  • Summit Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1100 holding.
  • CX Institutional first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 37 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.